Analyst Rating Update on Prothena Corporation plc (PRTA)

Prothena Corporation plc (NASDAQ:PRTA) has an average broker rating of 1.17, which is interpreted as a Strong Buy, as rated by 6 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.

Prothena Corporation plc (NASDAQ:PRTA) : 6 Wall Street analysts covering Prothena Corporation plc (NASDAQ:PRTA) believe that the average level the stock could reach for the short term is $73.5. The maximum price target given is $95 and the minimum target for short term is around $55, hence the standard deviation is calculated at $14.31.

For the current week, the company shares have a recommendation consensus of Buy.

Prothena Corporation plc (NASDAQ:PRTA): stock turned positive on Tuesday. Though the stock opened at $34.85, the bulls momentum made the stock top out at $37.19 level for the day. The stock recorded a low of $34.3 and closed the trading day at $36.19, in the green by 7.04%. The total traded volume for the day was 670,757. The stock had closed at $33.81 in the previous days trading.

In an insider trading activity,The director of Prothena Corp Plc, Selkoe Dennis J. sold 5,000 shares at $45 on May 23, 2016. The Insider selling transaction had a total value worth of $225,000. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.

Prothena Corporation Public Limited Company is an Ireland-based, late-stage clinical biotechnology company. The Company is focused on the discovery, development and commercialization of protein immunotherapy programs for the treatment of diseases that involve amyloid or cell adhesion. The Companys research and development pipeline includes three therapeutic antibody programs, such as NEOD001 for the treatment of AL amyloidosis; PRX002 in collaboration with Roche, for the treatment of Parkinsons disease and other related synucleinopathies, and PRX003 for the treatment of psoriasis and other inflammatory diseases. The Companys pipeline also includes several late discovery stage programs for which it is testing antibodies in preclinical models of diseases related to amyloid or cell adhesion.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.